Gastrointestinal adverse events and hepatobiliary adverse events were more common in the ceftriaxone group than in the placebo group ( gastrointestinal , @ of @ -LSB- @ % -RSB- ceftriaxone vs @ of @ -LSB- @ % -RSB- placebo , p = @ ; hepatobiliary , @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- , p < @ ) .